Clinical observation on rabeprazole combined with mosapride in treatment of reflux esophagitis
Jingyan Shen
Abstract
Jingyan Shen
Abstract
Objective To study the the efficacy and safety of joint rabeprazole mosapride treatment of reflux esophagitis(RE). Methods 110 patients Confirmed by endoscopy reflux esophagitis were randomly divided into treatment group and control group 55 cases. Treatment group:oral rabeprazole 10mg, sooner or later, a second fasting taking each mosapride 5mg,3 times/day, fasting and a half hours to take; control group: omeprazole 20mg/day, taken before meals ,mosapride taking followed. 2 groups of patients were completed 6 weeks of treatment ,the clinical efficacy and safety were observed. Results The clinical total effective rate of symptom relief( symptom improvement and endoscopic remission and mucosal lesions ) were 94.5% for the treatment group ( 52/55 ), control group 76.4% ( 42/55), the efficiency of the treatment group was superior in the control group ( P < 0.05 ). Conclusion Rabeprazole joint mosapride treatment of reflux esophagitis could improve symptoms rapidly,and clinical efficacy was superior to omeprazole mosapride treatment of reflux esophagitis, and was safe and reliable. Key words: Rabeprazole; Mosapride ; Esophagitis, reflux
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To study the the efficacy and safety of joint rabeprazole mosapride treatment of reflux esophagitis(RE). Methods 110 patients Confirmed by endoscopy reflux esophagitis were randomly divided into treatment group and control group 55 cases. Treatment group:oral rabeprazole 10mg, sooner or later, a second fasting taking each mosapride 5mg,3 times/day, fasting and a half hours to take; control group: omeprazole 20mg/day, taken before meals ,mosapride taking followed. 2 groups of patients were completed 6 weeks of treatment ,the clinical efficacy and safety were observed. Results The clinical total effective rate of symptom relief( symptom improvement and endoscopic remission and mucosal lesions ) were 94.5% for the treatment group ( 52/55 ), control group 76.4% ( 42/55), the efficiency of the treatment group was superior in the control group ( P < 0.05 ). Conclusion Rabeprazole joint mosapride treatment of reflux esophagitis could improve symptoms rapidly,and clinical efficacy was superior to omeprazole mosapride treatment of reflux esophagitis, and was safe and reliable. Key words: Rabeprazole; Mosapride ; Esophagitis, reflux
Key concepts: Mosapride, Rabeprazole, Medicine, Reflux esophagitis, Omeprazole, Gastroenterology, Internal medicine, Reflux